We have recently learned of new developments with respect to the ongoing shortage of SABRIL (vigabatrin) that may affect some epilepsy patients in Canada.

 The product shortage now affects SABRIL stock of the 500mg tablets. Stock of SABRIL (vigabatrin) powder for oral formulation, the subject of the previously reported shortage in July 2022, has been replenished and is now available once again.

Click here to read the communication from the drug company.  A French version is available here 

 Patients affected by this shortage are encouraged to reach out and consult with their healthcare professional, who can make a decision about their treatment plan. Additional questions and medical information inquiries can also be directed to Lundbeck Canada Medical Information at 1-866-880-4636 or canadamedicalinformation@lundbeck.com.